Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 54

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 54
---
in the 2013 case Assoc. for Molecular Pathology v. Myriad Genetics, Inc., the U.S. Supreme Court held that certain claims to DNA
molecules are not patentable. While we do not believe that any of the patents owned or licensed by us will be found invalid based on this
decision, we cannot predict how future decisions by the courts, Congress or the USPTO may impact the value of our patents.

Obtaining and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees, renewal fees, annuities
fees, and various other governmental fees on patents and/or patent applications are due to be paid to the USPTO and foreign patent agencies
in several stages over the lifetime of the patent and/or patent application. The USPTO and various foreign governmental patent agencies
also require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application
process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable
rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in
partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse
of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits,
non-payment of fees, and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications
covering our diagnostic tests or therapeutic product candidates, our competitive position would be adversely affected.

Patent terms may be inadequate to protect our competitive position on our diagnostic tests or therapeutic product candidates for an adequate amount of time.

The term of any individual patent depends on applicable
law in the country where the patent is granted. In the U.S., provided all maintenance fees are timely paid, a patent generally has a term
of 20 years from its application filing date or earliest claimed non-provisional filing date. Extensions may be available under certain
circumstances, but the life of a patent and, correspondingly, the protection it affords is limited. Even if we or our licensors obtain
patents covering our diagnostic tests and therapeutic product candidates, when the terms of all patents covering